

Supplemental Material

Supplemental Table. Demographics, descriptive statistics and imaging outcomes in subset of women diagnosed with breast cancer.

	Pre-Treatment (n=13)	Non- Anthracycline Treated (n=17)	Anthracycline Treated (n=21)	ANOVA p-value
Age at exam, years	54±12	57±12	56±10	0.76
Race				0.22
White	8 (62%)	15 (88%)	16 (76%)	
Black	5 (38%)	2 (12%)	5 (24%)	
Female	13 (100%)	17 (100%)	21 (100%)	
Breast Cancer	13 (100%)	17 (100%)	21 (100%)	
Time since Chemotherapy, years	-	2.6±0.9	3.3±1.9	0.17*
Radiation Therapy	-	13 (76%)	18 (86%)	0.68*
CVD Risk Factors				
Known CAD	-	1 (6%)	-	0.59
Diabetes	2 (15%)	2 (12%)	3 (14%)	0.96
Hyperlipidemia	3 (23%)	4 (24%)	5 (24%)	0.99
Hypertension	3 (23%)	6 (35%)	7 (33%)	0.75
Body mass index, kg/m²	28.7±5.5	28.7±7.6	27.8±4.7	0.87
Hematocrit, %	36±3	39±4	37±4	0.19
Received gadolinium	8 (62%)	11 (65%)	12 (57%)	0.89
CMR Results				
LVEDV index, ml/m ²	62±14	57±13	58±15	0.53
LVESV index, ml/m ²	26±8	23±7	26±8	0.28
LV SV index, ml/m ²	37±9	34±8	31±10	0.28
LVEF, %	59±7	60±7	54±9	0.03
LV mass index, g/m ²	50±6	45±9	47±10	0.38
Native T1, ms	1070±32	1041±28	1037±27	<0.01
ECV, %	30.2±2.5	29.5±4.4	33.2±6.0	0.17
*p-value comparing survivors only. CVD = cardiovascular disease, CAD = coronary artery disease, CMR = cardiovascular magnetic resonance, LV = left ventricular, EDV = end diastolic volume, ESV = end systolic volume, EF = ejection fraction, ECV = extracellular volume fraction. Data presented as mean ± std or n (%). Cross-sectional data (participants in a unique group, no serial data).				

Supplemental Figure. Breast cancer survivors treated with anthracycline-based chemotherapy trended to have a higher extracellular volume than breast cancer survivors treated with non-anthracycline based chemotherapy or newly diagnosed breast cancer patients prior to receipt of cancer treatment therapies.

